ISAP Researchers' Profiles

Maureen P. Hillhouse, Ph.D.

Maureen Hillhouse, Research Psychologist. Dr. Hillhouse joined the UCLA Drug Abuse Research Center (DARC) as a NIDA-funded pre-doctoral fellow in 1996, with interests in alcoholism and adolescence. After successful completion of her dissertation in the area of Learning and Behavior in the Department of Psychology at UCLA, Dr. Hillhouse remained at DARC as an Assistant Research Psychologist. She served as Project Director for several research projects addressing treatment outcome, collaborated on numerous peer-reviewed, published papers, and was awarded a NIDA-funded B-start grant to study a developing cognitive model of recovery. Currently, Dr. Hillhouse’s research is in the area of clinical trials, testing medications for the treatment of substance dependence.  Current projects include serving as investigator on the NIDA Clinical Trials Network in the Pacific Node under the direction of Dr. Walter Ling, a NIDA-funded project examining psychosocial treatments added to pharmacotherapy with buprenorphine for opioid dependence, and a double-blind, placebo-controlled pharmacotherapy trial investigating treatment outcome in methamphetamine-dependent study participants. Dr. Hillhouse also serves as a Committee Member for the UCLA Medical-3 Institutional Review Board; and participates as a consultant for the Prism Awards, sponsored by NIDA and the Entertainment Industries Council.

Education and Training

  • California State University, Northridge, B.A., 1991, Psychology
  • University of California, Los Angeles, M.A., 1993, Psychology
  • University of California, Los Angeles, Ph.D., 1998, Psychology

Specialties

  • Treatment Outcome (pharmacotherapy, psychosocial treatment trials)

Contact Info

UCLA Integrated Substance Abuse Programs
1640 S. Sepulveda Blvd., Suite 120
Los Angeles, CA 90025
hillhous@ucla.edu

Selected Publications

  1. Fiorentine, R., & Hillhouse, M. P. (1999). Drug treatment effectiveness and counselor empathy: Exploring the effects of gender and ethnic congruency. Journal of Drug Issues, 29, 59-74.
  2. Fiorentine, R., Pilati, M., & Hillhouse, M. P. (1999). Drug treatment outcomes: Investigating the long-term effects of sexual and physical abuse histories. Journal of Psychoactive Drugs, 31, 363-372.
  3. Fiorentine, R., & Hillhouse, M. P. (2000). Drug treatment and twelve-step program participation: The additive effects of integrated recovery activities. Journal of Substance Abuse Treatment, 18, 65-74.
  4. Fiorentine, R., & Hillhouse, M. P. (2000). Exploring the additive effects of drug treatment and 12-step involvement: Does 12-step ideology matter? Substance Use and Misuse, 35, 367-397.
  5. Fiorentine, R., & Hillhouse, M. P. (2000). Self-efficacy, expectancies, and abstinence acceptance: Further evidence for the Addicted-Self Model of cessation of alcohol and drug dependent behavior. The American Journal of Drug and Alcohol Abuse, 26, 497-521.
  6. Hillhouse, M. P., Grella, C. P., & Anglin, M. D. (2000). Personality characteristics of adolescents in treatment for alcohol and other drug misuse: Gender and ethnic differences. NIDA Research Monograph 180, 81. Bethesda, MA: U.S. Department of Health and Human Services.
  7. Fiorentine, R., & Hillhouse, M. P. (2000). Drug treatment and Twelve-Step program participation: The additive effects of integrated recovery activities. NIDA Research Monograph 180, 147. Bethesda, MA: U.S. Department of Health and Human Services.
  8. Hillhouse, M. P. & Fiorentine, R. (2001). 12-Step participation and effectiveness: Do gender and ethnic differences exist? Journal of Drug Issues, 31, 767-780.
  9. Fiorentine, R., Hillhouse, M. P., & Anglin, M. D. (2001). Drug use careers and treatment outcome. In C. Leukefeld, F. Tims, & D. Farabee (eds.), Clinical and policy responses to drug offenders (pp. 273-282). New York, Springer.
  10. Fiorentine, R., & Hillhouse, M. P. (2001). The Addicted-Self Model of alcohol and drug dependent behavior cessation: A theory of “natural” recovery? Journal of Drug Issues, 31, 495-424.
  11. Fiorentine, R., & Hillhouse, M. P. (2003). Why extensive participation in treatment and 12-Step programs is associated with the cessation of addictive behaviors: An application of the Addicted-Self Model of recovery. Journal of Addictive Diseases, 22, 35-55.
  12. Fiorentine, R., & Hillhouse, M. P. (2003). Replicating the Addicted-Self Model of Recovery. Addictive Behaviors, 28, 1068-1080.
  13. Fiorentine, R. & Hillhouse, M. P. (2003). When low self-efficacy is efficacious: Toward an Addicted-self Model of Cessation of Alcohol- and Drug-dependent Behavior. American Journal on Addictions, 12, 346-364.
  14. Rawson, R., Sodano, R., & Hillhouse, M. (2004). Assessment of amphetamine use disorders. In D. Donovan & G. A. Marlatt (Eds.), Assessment of addictive disorders. New York: The Guilford Press.
  15. Hillhouse, M. P. & Fiorentine, R. (2004). The addicted-self model of addictive behavior cessation: does it predict recovery for gender, ethnic, age, and drug preference subgroups? The American Journal on Addictions, 13, 268-280.
  16. Ling, W., Amass, L., Shoptaw, S., Annon, J. J., Hillhouse, M., Babcock, D., Grigham, G., Harrer, J., Reid, M., Muir, J., Buchan, B., Orr, D., Woody, G., Krejci, J., and the Buprenorphine Study Protocol Group. (2005). A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction, 100, 1090-1100.
  17. Torrington, M. A., Domier, C. P., Hillhouse, M. & Ling, W. (2007). Buprenorphine 101: Treating opioid dependence with buprenorphine in an office-based setting. Journal of Addictive Diseases, 26, 93-99.
  18. Hillhouse, M. P.; Marinelli-Casey, P.; Gonzales, R.; Ang, A., Rawson, R. A., & the Methamphetamine Treatment Project Corporate Authors. (2007). Predicting in-treatment performance and post-treatment outcomes in methamphetamine users. Addiction, 102 (suppl. 1), 84 - 95.
  19. Marinelli-Casey, P., Gonzales, R., Hillhouse, M. P., Ang, A., & Rawson, R. A. (2008) The effectiveness of drug court treatment for methamphetamine dependence: Treatment response and post-treatment outcomes. Journal of Substance Abuse Treatment, 34, 242-248.
  20. Glasner-Edwards, S., Mooney, L. J., Marinelli-Casey, P., Hillhouse, M., Ang, A., Rawson, R., & the Methamphetamine Treatment Project corporate authors. (2008). Risk Factors for Suicide Attempts in Methamphetamine Dependent Patients. American Journal on Addictions, 17, 24-27.
  21. Glasner-Edwards, S., Marinelli-Casey, P., Hillhouse, M., Ang, A., Mooney, L. J., Rawson, R., & the Methamphetamine Treatment Project Corporate Authors. (2009). Depression Among Methamphetamine Users: Association with Outcomes from the Methamphetamine Treatment Project at 3-year Follow-up. Journal of Nervous & Mental Disease, 197; 225-231.
  22. Glasner-Edwards, S., Mooney, L.J., Marinelli-Casey, P., Hillhouse, M., Ang, A., & Rawson, R. (2008). Identifying methamphetamine users at risk for major depressive disorder: findings from the MTP at 3-year follow-up. American Journal on Addictions, 17, 99-102.
  23. Glasner-Edwards, S., Mooney, L. J., Marinelli-Casey, P., Hillhouse, M., Ang, A., & Rawson, R. (2008). Clinical course and outcomes of methamphetamine-dependent adults with psychosis. Journal of Substance Abuse Treatment, 35, 445-450.
  24. Gonzales, R., Marinelli-Casey, P., Hillhouse, M., Hunter, J., Rawson, R. A., Mooney, L., & Ang, A. (2008). Hepatitis A and B infection among methamphetamine-dependent users. Journal of Substance Abuse Treatment, 35, 351-352.
  25. Messina, N., Marinelli-Casey, P., Hillhouse, M., Rawson, R. A., & Hunter, J. (2010). Childhood adverse events and health outcomes among methamphetamine-dependent men and women. Accepted for publication, International Journal of Mental Health and Addiction, 6, 522-536.
  26. Ling, W., Hillhouse, M., Domier, C., Doraimani, G., Hunter, J., Thomas, C., Jenkins, J., Hasson, A., Annon, J., Saxon, A., Selzer, J., Boverman, J., & Bilangi, R. (2009). Buprenorphine tapering schedule and illicit opioid use. Addiction, 104, 256-265.
  27. Mooney, L.J., Glasner-Edwards, S., Marinelli-Casey, P., Hillhouse, M., Ang, A., Hunter, J., Haning, W., Colescott, P., Ling, W., & Rawson, R.A. (2009). Health conditions in methamphetamine-dependent adults 3 years after treatment. Journal of Addiction Medicine, 3, 155-163.
  28. Glasner-Edwards, S., Mooney, L.J., Marinelli-Casey, P., Hillhouse, M., Ang, A., & Rawson, R.A. (2010). Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug and Alcohol Review, 29, 12-20.
  29. Hillhouse, M., Domier, C. P., Chim, D., & Ling, W. (2010). Provision of ancillary medications during buprenorphine detoxification does not improve treatment outcomes. Accepting for publication, Journal of Addictive Diseases.
  30. Glasner-Edwards, S., Mooney, L., J., Marinelli-Casey, P., Hillhouse, M., Ang, A.,, Rawson, R. (2010). Anxiety disorders among methamphetamine dependent adults: Association with post-treatment functioning. The American Journal on Addictions, 19, 385-390.
  31. Ling, W., Jacobs, P., Hillhouse, M., Hasson, A., Thomas, C., Freese, T., Sparenborg, S., McCarthy, D., Tai, B., Weiss, R., Saxon, A., Cohen, A., Straus, M., Brigham, G., Liu, D., McLaughlin, P. (2010). From research to the real world: Buprenorphine in the decade of the CTN. Journal of Substance abuse Treatment, 38 (Supple 1), S53-61.
  32. Potter, J. S., Chakrabarti, A., Domier, C.P., Hillhouse, M., Weiss, R., & Ling, W. (2010). Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: Secondary analyses from the Clinical Trials Network. Journal of Substance Abuse Treatment, 38 (Suppl 1), S80-86.
  33. Brown, E. S., Tirado, C., Minhajuddin, A., Hillhouse, M., Adinoff, B., Ling, W., Doraimani, G., & Thomas, C. (2010). Association of race and ethnicity with withdrawal symptoms, attrition, opioid use, and side-effects during buprenorphine therapy. Journal of Ethnicity in Substance Abuse, 9, 106-114.
  34. Glasner-Edwards, S., Mooney, L. J., Marinelli-Casey, P., Hillhouse, M., Ang., A., & Rawson, R. A. (2011). Bulimia nervosa among methamphetamine dependent adults: Association with outcomes three years after treatment. Eating Disorders, 19, 259-269.
  35. Ling, W., Mooney, L., & Hillhouse, M. (2011). Prescription opioid abuse, pain, and addiction: Clinical issues and implications. Drug and Alcohol Review, 30, 300-305.
  36. Hillhouse M, Canamar CP, Doraimani G, Thomas C, Hasson A, Ling W. (2011). Participant characteristics and buprenorphine dose.  Am J Drug Alcohol Abuse, 37, 453-459. PMID: 21854290
  37. Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, Hillhouse M, Brady KT, Ling W. (2011). Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse, 37, 313-323. PMID: 21854273
  38. Miotto, K., Hillhouse, M., Donovik, R., Cunningham-Rathner, J., Charuvastra, C., Torrington, M., Esagoff, A. E., & Ling, W. (2012). Comparison of buprenorphine treatment for opioid dependence in three settings. In press, Journal of Addiction Medicine.
  39. Compton, P., Canamar, C. P., Hillhouse, M., & Ling, W. (2012). Hyperalgesia in heroin dependent patients and the effects of opioid substitution Therapy. In press, Journal of Pain.
  40. Ling, W., Shoptaw, S., Hillhouse, M., Bholat, M. A., Charuvastra, C., Heinzerling, K., Chim, D., Annon, J., Dowling, P. T., & Doraimani, G. (In press). Double-blind placebo-controlled evaluation of the Prometa protocol for methamphetamine dependence. In press, Addiction.
  41. Ling, W., Hillhouse, M., Jenkins, J., Miotto, K., Torrington, M., & Chapleo, C. (2012). Comparisons of analgesic potency and side effects of buprenorphine and buprenorphine with ultra-low-dose naloxone. Accepted for publication, Journal of Addiction Medicine.

Last updated - 02/08/2012

Click here to view other profiles.

Top of Page